- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01415544
Comparison of Noninvasive Blood Glucose Concentrations Relative to Finger Capillary Blood Glucose References
An Evaluation and Comparison of Noninvasive Blood Glucose Concentrations Relative to Finger Capillary Blood Glucose References
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Currently, individuals with diabetes must use an invasive finger stick methodology for the determination of their blood glucose levels. Although current technology glucose meters use a smaller amount of blood than older generation meters, the pain and inconvenience associated with this invasive measurement is the number one reason cited for inadequate or infrequent blood glucose monitoring. In fact up to 67% of patients with diabetes fail to routinely monitor their blood glucose levels. A survey of 1895 patients showed that finger soreness was the most common reason given for self-reported noncompliance with testing recommendations, followed by pain, inconvenience, fear of needles, and "other" (including cost), (Diabetes Care August 2001 vol. 24 no. 8 1502-1503). The ability to make a painless blood glucose measurement using only light would address the pain and inconvenience issues associated with current technology glucose meters.
The initial application of the technology is associated with the monitoring of Gestational Diabetes. The International Association of Diabetes and Pregnancy Study Groups (IADPSG) recently released recommendations for diagnosing gestational diabetes, as well as clarifying the benefits of treatment (Diabetes Care, 2010;33:676-682). The IADPSG cited research that found significant graded relationships between increasing maternal glucose levels and the frequency of four primary and five secondary outcomes. For example, with a 1-standard deviation increase in maternal fasting, 1-hour, and 2-hour plasma glucose levels, there was a corresponding 38%, 46%, and 38% increased risk, respectively, in the primary outcome of birth weight >90th percentile, and a 5%, 18%, and 16% increased risk, respectively, of the secondary outcome of premature delivery before 37 weeks gestation (N Engl J Med 2008;358:1991-2002).
Studientyp
Einschreibung (Voraussichtlich)
Kontakte und Standorte
Studienorte
-
-
New Mexico
-
Albuquerque, New Mexico, Vereinigte Staaten, 87106
- Lovelace Scientific Resources
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Female at least 20 years of age but not older than 50 years of age
- Female with Type I or Gestational diabetes based on ADA criteria
- Female with Type II diabetes and A1c of greater than 7.0 as measured on a Bayer A1C Now meter
- May include female healthy volunteers.
Exclusion Criteria:
- Subject requires hemo-dialysis
- Severe heart disease as evidenced by peripheral edema
- Liver disease as evidenced by jaundice
- Active alcohol or drug abuse
- Body Mass Index (BMI) > 35 kg/m2
- Hand size too large to fit in the optical measurement instrumentation
- Middle finger width of less than 5 mm
- Skin damage at optical sampling site on hand
- Currently taking prednisone or other systemic steroids
- Tattoo at the optical sampling site
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
---|
Type 2 Diabetes
Those previously diagnosed with type 2 diabetes
|
Type 1 Diabetes
Those previously diagnosed with type 1 diabetes
|
Gestational Diabetes
Those that are currently diagnosed with gestational diabetes
|
Healthy Human Volunteers
Those that have not been diagnosed with any type of diabetes
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Calibrate near-infrared spectroscopy-based glucose meter
Zeitfenster: 1 year
|
The collection of capillary blood glucose and noninvasive data will allow the calibration of the noninvasive systems and subsequently evaluate performance via a validation study.
The paired NIR spectrum and blood reference data acquired during calibration will be processed using multivariate regression techniques to create a calibration model.
Results will be compared using a Clark error grid.
|
1 year
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Compare Noninvasive to invasive techniques
Zeitfenster: 1 year
|
Comparison of noninvasive glucose measurement performance versus standard invasive reference.
Invasive measurements are made by obtaining capillary blood glucose measurements and then measuring blood on a Yellow Springs Instrument (YSI).
Due to the fact that instrumentation drift and subject physiological changes can adversely influence measurement performance, the study is specifically designed to examine performance over an appropriate period of time with a reasonable distribution of subject variance.
Results will be compared using a Clark error grid.
|
1 year
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Walter Forman, MD, Lovelace Scientific Resources
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 10-0020
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Diabetes Typ 1
-
Eledon PharmaceuticalsZurückgezogenSpröder Diabetes mellitus Typ 1Vereinigte Staaten
-
Shanghai Jiao Tong University School of MedicineRekrutierung
-
Hadassah Medical OrganizationUnbekanntUnkontrollierte Typ-1-Diabetiker
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)AbgeschlossenDiabetes mellitus Typ 1 | T1DM | T1D | Neu aufgetretener Diabetes mellitus Typ 1Vereinigte Staaten, Australien
-
Shanghai Changzheng HospitalRekrutierungSpröder Diabetes mellitus Typ 1China
-
Capillary Biomedical, Inc.AbgeschlossenDiabetes mellitus, Typ 1 | Diabetes Typ 1 | Diabetes mellitus Typ 1 | Diabetes mellitus, insulinabhängig, 1Australien
-
Spiden AGDCB Research AGRekrutierungDiabetes mellitus Typ 1 | Diabetes mellitus Typ 1 mit Hypoglykämie | Diabetes mellitus Typ 1 mit HyperglykämieSchweiz
-
Capillary Biomedical, Inc.BeendetDiabetes Typ 1 | Diabetes mellitus Typ 1 | Diabetes mellitus, Typ I | Diabetes mellitus, insulinabhängig, 1 | IDDMÖsterreich
-
Instytut Diabetologii Sp. z o.o.National Center for Research and Development, Poland; Nalecz Institute of Biocybernetics...UnbekanntDiabetes mellitus Typ 1 mit Hyperglykämie | Diabetes mellitus Typ 1 mit HypoglykämiePolen
-
Poznan University of Medical SciencesUnbekanntDiabetes mellitus Typ 1 | Remission von Typ-1-Diabetes | Chronische Komplikationen von DiabetesPolen